Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
30.06
+2.06 (7.36%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Damora Therapeutics Employees
Damora Therapeutics had 7 employees as of December 31, 2025. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$34,464,286
Market Cap
1.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 2 | 40.00% |
| Dec 31, 2024 | 5 | -8 | -61.54% |
| Dec 31, 2023 | 13 | -32 | -71.11% |
| Dec 31, 2022 | 45 | 5 | 12.50% |
| Dec 31, 2021 | 40 | 12 | 42.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Immunocore Holdings | 524 |
| Maravai LifeSciences Holdings | 415 |
| Intellia Therapeutics | 377 |
| Vir Biotechnology | 367 |
| Syndax Pharmaceuticals | 298 |
| Lakefront Biotherapeutics NV | 196 |
| Stoke Therapeutics | 170 |
DMRA News
- 4 days ago - Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Damora Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Damora Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Damora Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - GlobeNewsWire
- 5 weeks ago - Damora Therapeutics price target raised to $40 from $35 at Wedbush - TheFly
- 6 weeks ago - Damora Therapeutics initiated with a Buy at Jefferies - TheFly
- 7 weeks ago - Damora Therapeutics completes redomestication to the Cayman Islands - TheFly